VC-backed Allakos goes public
San Carlos, California-based Allakos, a developer of antibodies that treat various eosinophil and mast cell related diseases, has raised about $128.4 million for its IPO after pricing its over 7.1 million shares at $18 per share. The stock began trading July 19, 2018 on the NASDAQ under the ticker symbol "ALLK." Goldman Sachs and Jefferies LLC are the lead underwriters. Allakos' pre-IPO backers include Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.
19 July 2018•1 min read
